MSBU will continue in Europe due to new indications there but it's obvious Novartis never took it seriously here. So sad but at least it's over now!
Best bonus plans are typically given when conditions are uncertain, to incentivize producers to hang in there. Maybe lucrative 2015 bonus for top tier reps? Need to bridge quality sales team until next product available, or new indication. If G gets new indication could be a game changer.